Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)
South Korea · Delayed Price · Currency is KRW 5,950.00
+130.00 (2.23%)
At close: Aug 24, 2026
Sinil Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 66,210 | 69,054 | 73,149 | 87,711 | 96,840 | 128,314 | |
Market Cap Growth | -7.18% | -5.60% | -16.60% | -9.43% | -24.53% | -48.11% |
Enterprise Value | 28,165 | 31,172 | 41,173 | 69,844 | 73,664 | 110,106 |
Last Close Price | 5820.00 | 6070.00 | 6234.53 | 7257.77 | 7822.22 | 10237.90 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 9.68 | 9.17 | 5.12 | 6.43 | 7.97 | 19.21 |
PS Ratio | 0.81 | 0.86 | 0.82 | 0.98 | 1.21 | 2.08 |
PB Ratio | 0.43 | 0.45 | 0.50 | 0.65 | 0.79 | 1.13 |
P/TBV Ratio | 0.44 | 0.46 | 0.51 | 0.66 | 0.80 | 1.15 |
P/FCF Ratio | 11.83 | 8.18 | 5.93 | 56.56 | 29.03 | 16.41 |
P/OCF Ratio | 7.01 | 5.96 | 3.22 | 5.79 | 7.08 | 11.50 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.34 | 0.39 | 0.46 | 0.78 | 0.92 | 1.78 |
EV/EBITDA Ratio | 2.19 | 2.33 | 1.98 | 3.61 | 4.07 | 8.80 |
EV/EBIT Ratio | 4.17 | 4.22 | 2.71 | 4.99 | 5.39 | 13.80 |
EV/FCF Ratio | 5.03 | 3.69 | 3.34 | 45.04 | 22.08 | 14.08 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.02 | 0.02 | 0.02 | 0.03 | 0.01 | 0.02 |
Debt / FCF Ratio | 0.04 | 0.03 | 0.04 | 0.35 | 0.04 | 0.04 |
Net Debt / Equity Ratio | -0.25 | -0.26 | -0.23 | -0.17 | -0.19 | -0.18 |
Net Debt / EBITDA Ratio | -2.96 | -2.91 | -1.60 | -1.18 | -1.28 | -1.64 |
Net Debt / FCF Ratio | -6.80 | -4.61 | -2.70 | -14.75 | -6.96 | -2.63 |
Asset Turnover | 0.49 | 0.48 | 0.56 | 0.60 | 0.59 | 0.49 |
Inventory Turnover | 1.92 | 2.06 | 2.15 | 2.42 | 2.40 | 2.22 |
Quick Ratio | 3.89 | 4.06 | 3.32 | 3.27 | 2.95 | 3.46 |
Current Ratio | 5.56 | 5.63 | 4.71 | 4.86 | 4.22 | 4.86 |
Return on Equity (ROE) | 4.63% | 5.04% | 10.16% | 10.57% | 10.28% | 6.05% |
Return on Assets (ROA) | 2.49% | 2.75% | 5.98% | 5.92% | 6.28% | 3.93% |
Return on Invested Capital (ROIC) | 5.28% | 5.71% | 11.69% | 12.04% | 11.77% | 6.88% |
Return on Capital Employed (ROCE) | 4.30% | 4.80% | 10.20% | 10.10% | 10.80% | 6.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 10.50% | 10.91% | 19.55% | 15.55% | 12.55% | 5.21% |
FCF Yield | 8.45% | 12.23% | 16.85% | 1.77% | 3.45% | 6.09% |
Payout Ratio | 31.60% | 29.16% | 13.74% | 8.15% | 8.89% | 15.73% |
Buyback Yield / Dilution | - | - | 0.02% | -3.94% | 1.05% | 0.11% |